Spiriva Safety Data Remains Key Hurdle For Respimat Inhaler
This article was originally published in The Pink Sheet Daily
Executive Summary
Conflicting findings to be discussed at Boehringer Ingelheim’s Aug. 14 advisory committee review of its tiotropium spray as FDA reviewers offer varying opinions on impact of new trial data.
You may also be interested in...
Boehringer’s Tiotropium Spray May Be Ready To Shed Mortality Issues
FDA Pulmonary-Allergy Drugs Advisory Committee to review NDA for COPD and will discuss safety results from trial comparing inhalation spray to powder.
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.
Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests
The rulemaking is supposed to formalize the Patent Trial and Appeal Board process, which has been in an interim status since a Supreme Court decision, giving manufacturers more ability to request oversight of the decisions.